X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18) 18
female (13) 13
index medicus (12) 12
middle aged (11) 11
oncology (11) 11
breast cancer (9) 9
breast neoplasms - drug therapy (9) 9
male (9) 9
chemotherapy (8) 8
surgery (8) 8
united states (8) 8
adult (7) 7
aged (7) 7
article (7) 7
cancer (7) 7
clinical trials (7) 7
care and treatment (5) 5
disease-free survival (5) 5
history (5) 5
medical colleges (5) 5
product development (5) 5
surgical adjuvant breast (5) 5
therapy (5) 5
treatment outcome (5) 5
abridged index medicus (4) 4
adjuvant treatment (4) 4
animals (4) 4
breast neoplasms - mortality (4) 4
breast neoplasms - surgery (4) 4
health maintenance organizations (4) 4
medicine, general & internal (4) 4
tamoxifen (4) 4
trastuzumab (4) 4
women (4) 4
états-unis (4) 4
analysis (3) 3
angiogenesis (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic agents, hormonal - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
aortic aneurysm, abdominal - surgery (3) 3
aortic aneurysm, thoracic - surgery (3) 3
biometry (3) 3
breast neoplasms - pathology (3) 3
breast neoplasms - radiotherapy (3) 3
cells, cultured (3) 3
chemotherapy, adjuvant (3) 3
civil war, 1861-1865 (3) 3
docetaxel (3) 3
double-blind method (3) 3
doxorubicin - administration & dosage (3) 3
drug therapy (3) 3
hematology, oncology and palliative medicine (3) 3
histoire (3) 3
historia (3) 3
internal medicine (3) 3
peripheral vascular disease (3) 3
public health (3) 3
quality of life (3) 3
quality-of-life (3) 3
radiation therapy (3) 3
tamoxifen - therapeutic use (3) 3
time factors (3) 3
trial (3) 3
vascular surgical procedures - methods (3) 3
womens health (3) 3
administration, oral (2) 2
age factors (2) 2
aged, 80 and over (2) 2
anthracyclines (2) 2
antibodies (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antibodies, monoclonal, humanized (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents, hormonal - administration & dosage (2) 2
aortic aneurysm, abdominal - complications (2) 2
aortic aneurysm, thoracic - complications (2) 2
aromatase inhibitors - administration & dosage (2) 2
aromatase inhibitors - therapeutic use (2) 2
articles (2) 2
aufsatzsammlung (2) 2
bevacizumab (2) 2
cancer surgery (2) 2
cancer therapies (2) 2
carcinoma (2) 2
carcinoma, ductal, breast - drug therapy (2) 2
carcinoma, ductal, breast - radiotherapy (2) 2
carcinoma, ductal, breast - surgery (2) 2
cardiac & cardiovascular systems (2) 2
cardiology and cardiovascular medicine (2) 2
cardiothoracic surgery (2) 2
causes (2) 2
cells (2) 2
clinical outcomes (2) 2
clinical-trials (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1183 - 1192
Summary Background We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | CELLS | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GW572016 | CHEMOTHERAPY PLUS TRASTUZUMAB | PERTUZUMAB | INHIBITOR | DOCETAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | United States | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Mastectomy | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Administration Schedule | Logistic Models | Treatment Outcome | Chi-Square Distribution | Breast Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Quinazolines - adverse effects | Trastuzumab | Health maintenance organizations | Neoadjuvant therapy | Medical colleges | Care and treatment | Cyclophosphamide | Anthracyclines | Adjuvant treatment | Breast cancer | Product development | Public health | Cancer | Index Medicus
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1037 - 1048
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10021, pp. 849 - 856
Summary Background Ductal carcinoma in situ is currently managed with excision, radiotherapy, and adjuvant hormone therapy, usually tamoxifen. We postulated... 
Internal Medicine | INTRADUCTAL BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | SURGICAL ADJUVANT BREAST | RADIATION-THERAPY | B-17 | Breast Neoplasms - surgery | Triazoles - administration & dosage | Triazoles - adverse effects | Thrombosis - chemically induced | Age Factors | Humans | Middle Aged | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Carcinoma, Ductal, Breast - drug therapy | Mastectomy, Segmental | Antineoplastic Agents, Hormonal - therapeutic use | Postmenopause | Female | Embolism - chemically induced | Aromatase Inhibitors - therapeutic use | Triazoles - therapeutic use | Aromatase Inhibitors - administration & dosage | Carcinoma, Ductal, Breast - surgery | Double-Blind Method | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Combined Modality Therapy | Breast Neoplasms - drug therapy | Breast Neoplasms - radiotherapy | Carcinoma, Ductal, Breast - radiotherapy | Tamoxifen - therapeutic use | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Lumpectomy | Medical colleges | Carcinoma | Radiation | Clinical trials | Postmenopausal women | Hormones | Tamoxifen | Radiotherapy | Biometry | Health maintenance organizations | Product development | Cancer | Chemotherapy | Womens health | Older people | Breast cancer | Radiation therapy | Cancer surgery
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10021, pp. 857 - 865
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10030, pp. 1837 - 1846
Journal Article
Journal of Thoracic and Cardiovascular Surgery, The, ISSN 0022-5223, 2009, Volume 138, Issue 1, pp. 163 - 171.e1
Objective Vascular endothelial growth factor, a critical factor in angiogenesis, mediates stem cell paracrine protective effects on ischemic myocardium.... 
Cardiothoracic Surgery | SURGERY | PHOSPHATIDYLINOSITOL 3-KINASE/AKT | CARDIAC & CARDIOVASCULAR SYSTEMS | ANGIOGENESIS | STAT3 | VEGF EXPRESSION | CARDIAC REPAIR | HEART | COLON-CANCER CELLS | RESPIRATORY SYSTEM | GENE-EXPRESSION | PROTEIN-KINASE PATHWAYS | SMOOTH-MUSCLE-CELLS
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2005, Volume 353, Issue 16, pp. 1673 - 1684
Journal Article